Early Detection of Polyps and Colon Cancer by Fluorescence Imaging - a Dose-finding Study
|ClinicalTrials.gov Identifier: NCT00285701|
Recruitment Status : Completed
First Posted : February 2, 2006
Last Update Posted : January 15, 2010
|Condition or disease||Intervention/treatment||Phase|
|Colorectal Cancer||Drug: hexaminolevulinate||Phase 1 Phase 2|
Colonoscopy is regarded as the "gold standard" for diagnosis of colorectal cancer. The sensitivity is uncertain but proposed to be (75-95%), however flat adenomas which are easily missed, are often not recognised. Fluorescence imaging may increase the sensitivity of standard white light colonoscopy by identifying more polyps and flat adenomas which will make the resection of adenomas more complete.
In this study hexaminolevulinate (HAL) will be administered locally as a photosensitiser, using different doses to find the optimal imaging conditions as well as making patient safety assessments.
Both standard white light and blue light (fluorescence) inspection will be performed.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||38 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Early Detection of Pre-malignant and Malignant Conditions in the Colon by Means of Fluorescence Endoscopy Using Local and Oral Sensitisation With Hexaminolevulinate (HAL) - a Dose Finding Study|
|Study Start Date :||July 2006|
|Primary Completion Date :||November 2007|
|Study Completion Date :||March 2008|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00285701
|Dept of Medicine, Munic-Hospital Pasing|
|Munic, Bayern, Germany|
|Principal Investigator:||Brigitte Mayinger, MD, PhD||Endlicher E, et al. Hexaminolevulinate-induced fluorescence endoscopy in patients with rectal adenoma and cancer: a pilot study. Gastrointestinal Endoscopy 2004;60:449-454|